This article was originally published on Cannabis & Tech Today and appears here with permission.
Medical marijuana (cannabis) may offer a promising option for patients with chronic itch, according to a new case study.
Chronic itch — known clinically as chronic pruritus — is characterized as an unrelenting and sometimes even debilitating sensation to itch, and often lowers the quality of life for those who have it.
Treating the condition has proved difficult because there are few Food and Drug Administration-approved therapies.
“Chronic itch can be an especially difficult condition to treat, with off-label therapeutics often utilized,” says Shawn Kwatra, assistant professor of dermatology at the Johns Hopkins University School of Medicine. “With the increased utilization of medical marijuana and our knowledge of the role of the endocannabinoid system [a complex cell-signaling system that regulates a variety of functions in the body] in chronic itch, we decided to try medical marijuana with a patient who failed several therapies and had few options left.”
Kwatra and colleagues examined an African American woman in her 60s with a 10-year history of chronic itch. The patient initially arrived at the Johns Hopkins Itch Center with complaints of extreme pruritus on her arms, legs, and stomach. A skin examination revealed numerous hyperpigmented, raised skin lesions. The patient tried several treatments — including systemic therapies, centrally acting nasal sprays, steroid creams, and phototherapy — but they all failed.
Kwatra says that using medical marijuana — either by smoking or in liquid form — provided the woman with nearly instantaneous improvement.
“We had the patient rate her symptoms using a numerical rating scale, where 10 is the worst itch and zero is no itch at all,” Kwatra says. “She started at 10 but dropped to 4 within 10 minutes after initial administration of the medical marijuana. With continued use of the cannabis, the patient’s itch disappeared altogether.”
The researchers believe that one of the active ingredients in medical marijuana, tetrahydrocannabinol — commonly known by its abbreviation THC — attaches itself to brain receptors that influence the nervous system. When this occurs, inflammation and nervous system activity decrease, which also could lead to a reduction in skin sensations such as itchiness.
Although conclusive studies have yet to be done to validate medical marijuana as an effective measure for the relief of previously unmanageable itch, Kwatra believes it warrants further clinical trials.
“Controlled studies are needed to determine dosing, efficacy, and safety for medical marijuana in the treatment of various human itch subtypes, and once those are performed, we will better understand which patients are most likely to benefit from this therapy,” he says.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.